PhRMA, top Democrats urge Supreme Court to take up abortion pill case

It’s a rar­i­ty these days to see the top phar­ma in­dus­try lob­by­ing group join Sen­ate and House De­mo­c­rat lead­ers and ar­gue the same side of any is­sue, but that’s the case with pe­ti­tion­ing the Supreme Court to take up a case on the abor­tion pill mifepri­s­tone. The case could have rip­ple ef­fects for all drug ap­provals.

PhRMA makes clear in an am­i­cus brief filed last Thurs­day that the Fifth Cir­cuit’s de­ci­sion in Au­gust to re­strict the use of mifepri­s­tone and its gener­ic ver­sions un­der the con­di­tions for use that ex­ist­ed in 2016, be­fore the FDA loos­ened some of the reg­u­la­tions, could lead to neg­a­tive con­se­quences for the phar­ma in­dus­try.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.